Research
Hormonal
Discontinuation of GLP-1/GIP agonist therapy leads to significant weight regain, indicating that obesity requires chronic pharmacological management rather than short-term courses.
If you stop taking these medications, you will likely regain the weight. Treat obesity like hypertension: it requires ongoing management. Do not stop without consulting your doctor.
StrongSupportsVERY_HIGH confidence
SURMOUNT-4 study... continued treatment group showed additional 1.9% weight loss, while placebo switch group regained 14.0% of weight.
Why this rating
Based on SURMOUNT-4 RCT.
Source
Recent advances in the pharmacological treatment of obesity
Ga Eun Nam · Journal of Korean Medical Association · 2025
DOI 10.5124/jkma.25.0058
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →